NL-OMON51590已完成不适用
A PHASE 1, OPEN-LABEL STUDY TO ASSESS THE MASS BALANCE AND PHARMACOKINETICS OF [14C]-IMU-838 IN HEALTHY MALE SUBJECTS - Mass balance study of [14C]-IMU-838
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Immunic AG
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Sex: Male subjects.
- •2. Age: 18 to 45 years, inclusive, at screening.
- •3. Body mass index (BMI): 18.0 to 30.0 kg/m2, inclusive, at screening.
- •4. Weight: >=50 kg at screening.
排除标准
- •1. Previous participation in the current study.
- •2. Employee of ICON plc or the Sponsor.
- •3. History of relevant drug and/or food allergies.
- •4. Using tobacco products within 60 days prior to the drug administration.
- •5. History of alcohol abuse or drug addiction (including soft drugs like
- •cannabis products) in the past 2 years.
研究者
相似试验
已完成
不适用
A Phase I open-label study to investigate the mass balance and biotransformation of a single oral 160 mg (100 µCi) dose of 14C-MDV3100 (ASP9785) in healthy male subjectsprostate carcinoom10038597prostate cancerNL-OMON35823Astellas Pharma6
招募中
1 期
[M24-427]ABBV-400 in Select Advanced Solid Tumor IndicationsHCC, PDAC, BTC, ESCC, BC, HNSCCJPRN-jRCT2031230534Yamagishi Chika220
已完成
不适用
Open-Label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism And Excretion Of [14C]-Etripamil Nasal Spray After a Single Dose to Healthy Male Subjects.NL-OMON50057Milestone Pharmaceuticals Inc8
已完成
不适用
A Phase 1 Study to Assess the Mass Balance, Excretion, and Pharmacokinetics of [14C]-GBT021601, an Oral Hemoglobin S Polymerization Inhibitor, in Healthy Participantssickle cell disease10038158sickle cell anemiaNL-OMON53865Global Blood Therapeutics, Inc.9
已完成
不适用
A phase I, open label study to investigate the absorption, metabolism and excretion of 14C-ESN-364 in healthy menopausal female volunteers.NL-OMON46563Ogeda6